Department of Medicine, McGill University Health Center, Cancer Research Program, Montreal, QC, H4A 3J1, Canada.
Department of Histology and Embryology, Chongqing Key Laboratory of Neurobiology, Third Military Medical University, Chongqing 400038, China.
Cell Signal. 2018 Jan;42:1-10. doi: 10.1016/j.cellsig.2017.10.002. Epub 2017 Oct 6.
The invasive and metastatic phenotypes of breast cancer correlate with high recurrence rates and poor survival outcomes. Transforming growth factor-β (TGFβ) promotes tumor progression and metastasis in aggressive breast cancer. Here, we identified the kisspeptin KiSS1 as a downstream target of canonical TGFβ/Smad2 pathway in triple negative breast cancer cells. We also found KiSS1 expression to be required for TGFβ-induced cancer cell invasion. Indeed, knockdown expression of KiSS1 blocked TGFβ-mediated cancer cell invasion as well as metalloproteinase (MMP9) expression and activity. Interestingly, Kisspeptin-10 (KP-10), the smallest active form of kisspeptin also stimulates cancer cell invasive behavior through activation of MAPK/Erk pathway. We described a positive feedback loop between KiSS1 and p21 downstream of TGFβ, further contributing to TGFβ-induced cancer cell invasion. Lastly, we explored both the clinical utility of KiSS1 as a lymph node involvement predictive tool and its potential as a therapeutic target. We found KiSS1 high expression to correlate with lymph node positive status. Furthermore, blocking KiSS1 using a specific small peptide antagonist (p234) impaired TGFβ-mediated cell invasion and MMP9 induction. Together, our results define an essential role of KiSS1 in regulating TGFβ pro-invasive effects and define KiSS1 as a therapeutic new target for triple negative breast cancer.
乳腺癌的侵袭和转移表型与高复发率和不良生存结局相关。转化生长因子-β(TGFβ)促进侵袭性乳腺癌的肿瘤进展和转移。在这里,我们确定了 kisspeptin KiSS1 是三阴性乳腺癌细胞中经典 TGFβ/Smad2 途径的下游靶标。我们还发现 KiSS1 表达是 TGFβ诱导的癌细胞侵袭所必需的。事实上,KiSS1 的敲低表达阻断了 TGFβ介导的癌细胞侵袭以及金属蛋白酶(MMP9)的表达和活性。有趣的是,kisspeptin-10(KP-10),kisspeptin 的最小活性形式,也通过激活 MAPK/Erk 途径刺激癌细胞侵袭行为。我们描述了 TGFβ 下游 KiSS1 和 p21 之间的正反馈回路,这进一步促进了 TGFβ 诱导的癌细胞侵袭。最后,我们探讨了 KiSS1 作为淋巴结受累预测工具的临床实用性及其作为治疗靶点的潜力。我们发现 KiSS1 的高表达与淋巴结阳性状态相关。此外,使用特异性小肽拮抗剂(p234)阻断 KiSS1 会损害 TGFβ 介导的细胞侵袭和 MMP9 诱导。总之,我们的结果定义了 KiSS1 在调节 TGFβ 促侵袭作用中的重要作用,并将 KiSS1 定义为三阴性乳腺癌的治疗新靶点。